Oncology clinical trials represent a higher share of clinical trials in the dataset for all countries, which is very much in keeping with oncology’s representation in the share of R&D expenditure. The data reflect a very competitive environment for clinical trials, with the UK closely competing with Japan, Canada, and other European countries. Again, 2016 raises a number of questions about clinical research, as it appears that a reduction in the number of trials initiated in oncology has occurred in every country except for the US, where even in the US the growth in the number of trials has eased.
Only commercial trials related to pharmaceutical drug development and molecular/biological entities were included. Collaborative trials were only included if one or more partners were a commercial organisation and all therapeutic areas were included in this analysis. Trials across multiple therapy areas were only included once and the therapy area in which they were included was determined by the trial’s main purpose for study.